-
公开(公告)号：US20160199341A1
公开(公告)日：2016-07-14
申请号：US15075697
申请日：2016-03-21
申请人： TRIS Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
CPC分类号： A61K31/245 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K9/5084 , A61K31/09 , A61K31/25 , A61K45/06 , A61K2300/00
摘要： A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
-
公开(公告)号：US20220202762A1
公开(公告)日：2022-06-30
申请号：US17573333
申请日：2022-01-11
申请人： Tris Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
摘要： A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
-
公开(公告)号：US09867797B2
公开(公告)日：2018-01-16
申请号：US15075697
申请日：2016-03-21
申请人： TRIS Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
IPC分类号： A61K9/22 , A61K31/245 , A61K31/25 , A61K31/09 , A61K9/20 , A61K9/24 , A61K9/28 , A61K45/06 , A61K9/00 , A61K9/50
CPC分类号： A61K31/245 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K9/5084 , A61K31/09 , A61K31/25 , A61K45/06 , A61K2300/00
摘要： A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
-
公开(公告)号：US20160008312A1
公开(公告)日：2016-01-14
申请号：US14863784
申请日：2015-09-24
申请人： TRIS Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
CPC分类号： A61K31/245 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K9/5084 , A61K31/09 , A61K31/25 , A61K45/06 , A61K2300/00
摘要： A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
摘要翻译： 描述了一种12小时的抗咳嗽释放固体片剂或胶囊，其包含基质中的苯甲酸盐被吸附物，其具有足够量的一种或多种药学上可接受的不依赖于释放pH的不溶性物质，以提供12小时改性释放曲线 苯甲酸酯，其中基本上没有苯甲酸盐从口腔中的片剂或胶囊释放，并且在体外溶出测定中测定的1小时内不超过约25％的苯甲酸酯释放。
-
公开(公告)号：US11890267B2
公开(公告)日：2024-02-06
申请号：US17573333
申请日：2022-01-11
申请人： Tris Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
IPC分类号： A61K9/20 , A61K31/245 , A61K9/00 , A61K9/24 , A61K9/28 , A61K31/09 , A61K31/25 , A61K45/06 , A61K9/50
CPC分类号： A61K31/245 , A61K9/0053 , A61K9/2009 , A61K9/209 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/09 , A61K31/25 , A61K45/06 , A61K9/2013 , A61K9/5084 , A61K31/245 , A61K2300/00 , A61K31/09 , A61K2300/00
摘要： A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
-
公开(公告)号：US20140271857A1
公开(公告)日：2014-09-18
申请号：US14282058
申请日：2014-05-20
申请人： TRIS Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
IPC分类号： A61K9/28 , A61K31/695 , A61K31/09 , A61K31/245
CPC分类号： A61K31/245 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K9/5084 , A61K31/09 , A61K31/25 , A61K45/06 , A61K2300/00
摘要： A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. The modified release may be provided by (a) a high melt temperature, water-insoluble wax or waxy substance, (b) a low viscosity hydrophilic polymer such a hydroxypropyl methylcellulose, (c) a reverse enteric coating, or combinations thereof. The benzonatate may be in an adsorbate with a silico or silicate or in a complex with a weak acidic ion exchange resin complex.
摘要翻译： 描述了一种12小时的抗咳嗽释放固体片剂或胶囊，其包含基质中的苯甲酸酯，其具有足够量的一种或多种药学上可接受的不依赖于释放pH的不溶性物质，以提供12小时改性释放曲线 苯甲酸酯，其中基本上没有苯甲酸盐从口腔中的片剂或胶囊释放，并且在体外溶出测定中测定的1小时内不超过约25％的苯甲酸钠释放。 改性释放可以通过（a）高熔体温度，水不溶性蜡或蜡质物质，（b）低粘度亲水性聚合物如羟丙基甲基纤维素，（c）反向肠溶衣或其组合来提供。 苯甲酸酯可以是具有硅或硅酸盐或与弱酸性离子交换树脂络合物的络合物的吸附物。
-
公开(公告)号：US11241411B2
公开(公告)日：2022-02-08
申请号：US16668479
申请日：2019-10-30
申请人： Tris Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
IPC分类号： A61K9/28 , A61K31/245 , A61K31/09 , A61K31/25 , A61K45/06 , A61K9/20 , A61K9/24 , A61K9/00 , A61K9/50
摘要： A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
-
公开(公告)号：US20200163926A1
公开(公告)日：2020-05-28
申请号：US16668479
申请日：2019-10-30
申请人： Tris Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
摘要： A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
-
公开(公告)号：US20180200221A1
公开(公告)日：2018-07-19
申请号：US15841785
申请日：2017-12-14
申请人： Tris Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
IPC分类号： A61K31/245 , A61K45/06 , A61K31/25 , A61K31/09 , A61K9/28 , A61K9/20 , A61K9/00 , A61K9/24 , A61K9/50
CPC分类号： A61K31/245 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K9/5084 , A61K31/09 , A61K31/25 , A61K45/06 , A61K2300/00
摘要： A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
-
公开(公告)号：US09408823B2
公开(公告)日：2016-08-09
申请号：US14863784
申请日：2015-09-24
申请人： TRIS Pharma Inc.
发明人： Andrea Nelson , Quin-Zene Chen , Harsh Mehta , Yu-Hsing Tu
IPC分类号： A61K9/22 , A61K31/245 , A61K31/09 , A61K9/24 , A61K9/28 , A61K45/06 , A61K9/00 , A61K9/20 , A61K9/50
CPC分类号： A61K31/245 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K9/5084 , A61K31/09 , A61K31/25 , A61K45/06 , A61K2300/00
摘要： A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
摘要翻译： 描述了一种12小时的抗咳嗽释放固体片剂或胶囊，其包含基质中的苯甲酸盐被吸附物，其具有足够量的一种或多种药学上可接受的不依赖于释放pH的不溶性物质，以提供12小时改性释放曲线 苯甲酸酯，其中基本上没有苯甲酸盐从口腔中的片剂或胶囊释放，并且在体外溶出测定中测定的1小时内不超过约25％的苯甲酸酯释放。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.019 秒)
